Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved

ALLSCHWIL/BASEL, SWITZERLAND - 04 May 2016 - At today's Annual General Meeting (AGM) of Actelion Ltd (SIX: ATLN), held in Basel, Switzerland, shareholders voted in favor of all proposals by the Board of Directors with a significant majority.

The meeting was attended by 246 shareholders. A total of 61'781'591 shares, or 54.13% of the total outstanding shares, was represented.

Led by the Chairman of the Board, Jean-Pierre Garnier, the company presented a review of the 2015 performance. The Chairman commented: "Over the last 15 months, Actelion has become a much stronger company. Firstly, the continued success of Opsumit exceeded our expectations all over the world. Secondly, we saw the timely FDA approval and successful US launch of Uptravi. Thirdly, we made solid progress in advancing key assets of our growing clinical pipeline of new drugs. This impressive scorecard was achieved while delivering a total shareholder return of 22% in 2015. Actelion is now very well positioned for a bright future. I would like to thank our management team and all our employees for their efforts in building Actelion, and our shareholders for their continued support."

The shareholders approved all of the Board's proposals, including the Annual Report 2015 as well as the Statutory and the Consolidated Financial Statements for 2015.

A proposal by the Board to distribute a dividend out of legal reserve originating from capital contribution in the amount of CHF 1.50 per registered share was passed by shareholders. The ex-dividend date will be 9 May 2016 and the payment will be made on 11 May 2016.

Shareholders endorsed the 2015 compensation report by way of consultative vote.

Shareholders also approved the aggregate maximum compensation for the Board of Directors (Non-Executive Directors) for the term until the AGM 2017 and the aggregate compensation amount for the Actelion Executive Committee (AEC) for the financial year 2017.
The shareholders granted discharge to all members of the Board of Directors and of the Executive Management and re-elected all members of the Board which stood for election for a term of office until the conclusion of the AGM 2017.

In addition, the shareholders elected Mr. Jean-Pierre Garnier as Chairperson of the Board and Ms. Herna Verhagen, Mr. Jean-Pierre Garnier, and Mr. John J. Greisch (Chair) to the Compensation Committee.

Following the AGM, the Board of Directors of Actelion comprises a total of 10 members: Jean-Pierre Garnier (Chairman), Juhani Anttila, Robert Bertolini, Jean-Paul Clozel, John J. Greisch, Peter Gruss, Michael Jacobi, Jean Malo, David Stout and Herna Verhagen.

BDO AG, represented by Mr. Marc Schaffner, was elected as Independent Proxy for a term of office until the conclusion of the AGM 2017.

Ernst & Young was re-elected as the company's statutory auditors for the business year 2016.



Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.

Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides in patients with cutaneous T-cell lymphoma.

Founded in late 1997, with now over 2,500 dedicated professionals covering all key markets around the world including the US, Japan, China, Russia and Mexico, Actelion has its corporate headquarters in Allschwil / Basel, Switzerland.

Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMIĀ®). All trademarks are legally protected.
For further information please contact:

Andrew Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62